View more on these topics

Independence of Woodford directors called into question

Woodford-Neil-700x450.jpgQuestions have been raised about the independence of two directors at Neil Woodford’s £855m Patient Capital Trust after a report in The Times reveals they have jobs at companies in which the fund owns a stake.

According to The Times, Patient Capital Trust chairwoman Susan Searle is also deputy chairwoman of Mercia Technologies, a quoted investment business that backs high-growth technology companies mainly in the Midlands and north of England.

She is also non-executive director at Benchmark Holdings, a supplier to the sustainable food and farming industries.

Meanwhile Patient Capital director Scott Brown is chief executive of Nexeon Limited, a battery materials and licensing company.

The news comes after the Patient Capital Trust reported a disappointing year.

According to results published on Tuesday, in the year to December shares in the fund fell by 7.2 per cent from 91p to 84.45p.

Meanwhile, the trust’s net asset value per share fell 2 per cent.

In the 2015 prospectus for Woodford Patient Capital, the firm said that while the directors would help oversee investment strategy, the potential for conflicts were recognised and none of the directors would manage assets in the portfolio on decide on individual stock picks.

A Woodford spokesman says: “When Woodford launched WPCT, it intentionally sought a board with extensive experience in the types of early-stage companies that the trust invests. It was also aware that by choosing such a board there might be situations where it invested in companies in which the directors were involved.”

He adds: “Woodford has robust procedures in place to ensure it mitigates any potential conflicts – the most crucial one being that the board has no involvement in the investment process or the day-to-day investment decisions, which are made solely by Neil and his team.”

The spokesman says in July 2016 two non-executive directors with experience in the investment trust sector were appointed to the board.

There was more bad news for Woodford on Monday, when shares in US biotech firm Prothena – which has exposure across all three of his funds – crashed by nearly 70 per cent.


Pile and a stack of coins with technical chart of financial instruments. A concept about currency trading or investing which investors must analyse and make the right decision for optimal profits.

SJP spends another £20m on platform upgrade

St James’s Place‘s platform upgrade is likely to cost the wealth management giant in excess of £170m, latest results reveal. Financial statements for 2017 show that the firm’s new Bluedoor system cost it nearly £22m for the year, up from £17m for 2016, as assets continue to migrate over to the new technology. While two-thirds […]

FSCS Interior 480

FSCS to pay back 2,700 clients of collapsed DFM Beaufort

The Financial Services Compensation Scheme will automatically compensate hundreds of clients of a collapsed discretionary fund manager, but other investors will have to wait another five months to get their money back. London-based Beaufort Securities has been investigated by both the FCA and US authorities. An indictment from the US Department of Justice alleges that […]

SJP sees funds under management dip in first quarter

The impact of weaker markets saw funds under management at St James’s Place drop in the first quarter of the year, when compared to its Q4 2017 result. In an update this morning, SJP says funds under management at 31 March 2018 were £89.9bn, down from £90.8bn in the previous quarter. On a year-on-year basis, funds under […]

Wells Street Journal: Pensions Regulator lobs a rotten Nest egg

Much has been made of the Government’s taxpayer funded campaign encouraging voters to back remaining in the EU. The Leave side predictably went ballastic when details emerged of the 14-page booklet sent to every household in the UK at a cost of £9m. Leading Brexiteers Boris Johnson and Nigel Farage also presumably received the handy […]


News and expert analysis straight to your inbox

Sign up


There are 3 comments at the moment, we would love to hear your opinion too.

  1. It doesn’t seem unreasonable to have directors with considerable specific experience in a sector the fund invests heavily in, in fact I’d worry if there weren’t directors with this qualification. I presume this is the case with pretty much every other investment trust too, but I’m not sure the Times was looking for a sensible and balanced story.

  2. It’s starting to look like a witch hunt for Neil Woodford. Of course he must be accountable for poor results, and I’m sure there are investors disgruntled with his recent performance. But the information that these WPCT directors were also involved in businesses the trust invests in was made known by Woodford. The information was publicly available.
    The maxim of ‘never let the facts get in the way of a good story’ seems to apply here.

Leave a comment